Across TCGA pan-cancer cohorts, FAM89A Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated FAM89A data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher FAM89A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FAM89A expression acts as an unfavorable survival marker.
COAD are the cancer types where FAM89A Mutation most reproducibly stratifies survival.